Cancer genomics creating infrastructure — targeted sequencing and resequencing enabling comprehensive analysis of cancer-associated genes and mutations identifying therapeutic targets, predicting treatment response, and guiding personalized cancer treatment through systematic genetic characterization, establishing targeted sequencing as essential cancer genomics infrastructure supporting precision oncology development and clinical implementation, with the Targeted Sequencing And Resequencing Market experiencing rapid expansion driven by cancer genomics adoption, personalized medicine emphasis, and expanding therapeutic targeting options enabling treatment selection based on genetic profiles.

Somatic mutation identification — targeted sequencing identifying somatic mutations (EGFR, KRAS, BRAF, TP53) in cancer tissue enabling detection of actionable mutations guiding targeted therapy selection and predicting treatment response in diverse cancer types. The mutation detection — where systematic mutation screening identifies druggable targets — supporting personalized treatment selection based on tumor genetics.

Gene fusion and rearrangement detection — targeted sequencing detecting gene fusions and chromosomal rearrangements (BCR-ABL, EML4-ALK, TMPRSS2-ERG) guiding targeted therapy selection and supporting molecular cancer subtyping. The fusion detection — where fusion identification enables specific targeted therapy — supporting precision cancer treatment.

Copy number variation analysis — targeted resequencing detecting gene amplifications and deletions affecting therapeutic targets and prognosis guiding treatment decisions in cancer management. The CNV analysis — where copy number assessment identifies therapeutic vulnerability — supporting cancer genomics-guided treatment.

As targeted cancer sequencing expands and genomic complexity increases, how should the oncology and genomics communities develop standardized reporting frameworks and therapeutic interpretation guidelines ensuring that genomic findings translate to actionable clinical recommendations — preventing genomic data generation without corresponding clinical utility or therapeutic guidance?

FAQ

What is the global targeted sequencing market size and cancer application landscape? Targeted sequencing market overview: market size: approximately USD 4–6 billion (2024); growing at 18–25% annually; projections: USD 8–12 billion by 2030; application: cancer: genomics: largest (~60%); hereditary: disease: approximately 20%; infectious: disease: approximately 10%; other: application (~10%); cancer: type: lung: cancer: largest (~25%); breast: cancer: approximately 20%; colorectal: cancer: approximately 15%; hematologic: malignancy: approximately 15%; other: cancer (~25%); sequencing: approach: panel: based: largest (~70%): targeted: gene: panel; whole: exome: approximately 20%: focused: exome: capture; custom: design: approximately 10%: specialized: panel; testing: scope: small: panel: <50 gene: approximately 30%; medium: panel: 50–300 gene: largest (~50%); large: panel: >300 gene: approximately 20%; end-user: hospital: laboratory: largest (~50%); reference: laboratory: approximately 30%; research: institution: approximately 15%; pharmaceutical: company: approximately 5%; geographic: North America (~45%): US: cancer: genomics: adoption: leader; Europe (~30%); Asia-Pacific (~20%): China: growing; market leader: Foundation: Medicine: FoundationOne: CDx: dominant; Illumina: TruSight: panel: sequencing; Thermo: Fisher: Ion: Torrent: targeted: sequencing; Guardant: Health: circulating: DNA: cancer: profiling; growth drivers: cancer: genomics: adoption: expanding: clinical: application; precision: oncology: treatment: selection: growing: emphasis; targeted: therapy: pipeline: expanding: actionable: mutation; genomic: tumor: profiling: standard: care: emerging.

How do targeted sequencing and resequencing identify cancer mutations and what factors affect detection? Targeted sequencing mechanism: panel: design: gene: selection: actionable: target: selection; cancer: driver: gene: selection: therapeutic: target: focus; coverage: depth: sequencing: depth: mutation: detection; high: coverage: >1000x: typical: high: sensitivity; sensitivity: mutation: detection: depth: dependent: variable; variant: allele: frequency: VAF: measurement: mutation: proportion; low: VAF: detection: high: coverage: requirement: sensitive: detection; background: mutation: sequencing: error: artifact: differentiation; filtering: algorithm: true: mutation: identification: artifact: filtering; annotation: variant: annotation: mutation: classification; pathogenicity: assessment: mutation: pathogenic: assessment; therapeutic: target: actionable: mutation: identification; variant: interpretation: mutation: clinical: significance; benign: variant: pathogenic: variant: classification; specific: mutation: EGFR: mutation: lung: cancer: targetable; KRAS: mutation: immunotherapy: resistance: marker; BRAF: mutation: melanoma: therapeutic: target; TP53: mutation: prognostic: marker: adverse; fusion: detection: gene: fusion: identification: targeted; BCR-ABL: chronic: myeloid: leukemia: fusion; EML4-ALK: lung: cancer: fusion; rearrangement: detection: structural: rearrangement: identification; amplification: detection: gene: amplification: copy: number: increase; HER2: amplification: breast: cancer: therapeutic; MYC: amplification: lymphoma: prognostic; deletion: detection: gene: deletion: copy: number: loss; PTEN: deletion: therapeutic: resistance: marker; tumor: mutational: burden: TMB: measurement: immunotherapy: response; microsatellite: instability: MSI: detection: immunotherapy: response; mismatch: repair: deficiency: MSI: associated; regulatory: requirement: FDA: approval: cancer: panel: variable; companion: diagnostic: FDA: approval: specific: therapy; clinical: validation: clinical: utility: demonstration; prospective: trial: validated: performance; quality: assurance: CAP: accreditation: requirement: laboratory.

#TargetedSequencingAndResequencingMarket #Cancer Genomics #Precision Oncology #Mutation Detection #Targeted Therapy #Personalized Medicine